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Human T-lymphotropic virus type-1 (HTLV-1) is a deltaretrovirus that causes adult T cell leukemia/lymphoma, and is implicated in a variety of
lymphocyte-mediated inflammatory disorders. HTLV-1 provirus has regulatory and accessory genes in four pX open reading frames. HTLV-1 pX
ORF-II encodes two proteins, p13II and p30II, which are incompletely defined in virus replication or pathogenesis. We have demonstrated that pX
ORF-II mutations block virus replication in vivo and that ORF-II encoded p30II, a nuclear-localizing protein that binds with CREB-binding
protein (CBP)/p300, represses CREB and Tax responsive element (TRE)-mediated transcription. Herein, we have identified p30II motifs important
for p300 binding and in regulating TRE-mediated transcription in the absence and presence of HTLV-1 provirus. Within amino acids 100–179 of
p30II, a region important for repression of LTR-mediated transcription, we identified a single lysine residue at amino acid 106 (K3) that
significantly modulates the ability of p30II to repress TRE-mediated transcription. Exogenous p300, in a dose-responsive manner, reverses p30II-
dependent repression of TRE-mediated transcription, in the absence or presence of the provirus, In contrast to wild type p300, p300 HAT mutants
(defective in histone acetyltransferase activity) only partially rescued p30II-mediated LTR repression. Deacetylation by histone deacetylase-1
(HDAC-1) enhanced p30II-mediated LTR repression, while inhibition of deacetylation by trichostatin A decreases p30II-mediated LTR repression.
Collectively, our data indicate that HTLV-1 p30II modulates viral gene expression in a cooperative manner with p300-mediated acetylation.
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Human T cell lymphotropic virus type 1 (HTLV-1) is the
etiologic agent of adult T cell leukemia/lymphoma (ATL), and
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doi:10.1016/j.virol.2006.07.002(HAM/TSP) and many immune-mediated disorders (Khan et
al., 2001; Franchini et al., 2003; Mahieux and Gessain, 2003).
Molecular mechanisms used by the virus to circumvent immune
elimination by the host and to facilitate lymphocyte prolifera-
tion are not fully understood. The genome of HTLV-1 encodes
Gag, Pol, and Env, the common structural and enzymatic
proteins characteristic of all retroviruses. Using alternative
splicing and alternate initiation codons, this complex retrovirus
makes several regulatory and accessory proteins encoded by
four open reading frames (ORFs) of the pX region (pX ORF I to
IV) between the env gene and the 3′ long terminal repeat (LTR)
(Michael et al., 2004; Franchini, 1995). ORF III and IV encode
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a nucleolar-localizing phosphoprotein, involved in nuclear
export of unspliced or singly spliced viral RNA (reviewed in
Younis and Green, 2005). Tax is a nuclear-localizing phospho-
protein that interacts with cellular transcription factors and
activates transcription from the viral promoter and enhancer
elements of various cellular genes associated with host cell
proliferation (reviewed in Pise-Masison et al., 2005; Marriott
and Semmes, 2005; Grassmann et al., 2005). pX ORFs I and II
also produce alternatively spliced forms of mRNA that encode
four accessory proteins, p12I, p27I, p13II, and p30II (Berneman
et al., 1992; Ciminale et al., 1992; Koralnik et al., 1992). Less is
known about the role of pX ORF I and ORF II in the replication
or pathogenesis of HTLV-1. However, pX ORFs I and II
mRNAs are present in infected cell lines and freshly isolated
cells from HTLV-1-infected subjects (Koralnik et al., 1992) and
in ATL and HAM/TSP patients (Cereseto et al., 1997).
Antibodies (Dekaban et al., 2000) and cytotoxic T cells
(Pique et al., 2000) against recombinant proteins or peptides
of the pX ORF I and II proteins are present in HTLV-1-infected
patients, and asymptomatic carriers.
p30II is a 241 amino acid protein that contains a highly
conserved bipartite nuclear localization signal (D'Agostino et
al., 1999), as well as serine-and-threonine-rich regions with
distant homology to transcription factors Oct-1 and -2, Pit-1, and
POU-M1 (Ciminale et al., 1992). Mutations in the ACH.p30IIFig. 1. p30II localizes to the nucleus and colocalizes with p300 in the nucleus of tran
slides (Fisher Scientific) at approximately 50% confluence 18 h prior to transfection
Superfect (Gibco BRL). At 48 h post-transfection, media were removed and cells we
FITC-conjugated anti-HA antibody (diluted 1:1000; Santa Cruz) and TRITC-conjug
Panel A represents the cytokeratin staining of the cells using Alexa Fluor® 633 phal
expression of p30II-HA (B) and p300 (C) was evaluated using Zeiss LSM 510 confo
These results represent a minimum of triplicate experiments.viral clone that insert an artificial termination codon in the p30II
mRNA, prevent the virus from obtaining typical proviral blood
levels in the rabbit model of infection (Bartoe et al., 2000;
Silverman et al., 2004). When provided in limiting concentra-
tions, p30II expression stimulates HTLV-1 LTR-driven reporter
gene activity, even in the presence of Tax, whereas higher
concentrations repressed LTR and CRE-driven reporter gene
activity (Zhang et al., 2000). p30II enhances the transforming
potential of Myc and transcriptionally activates the human
cyclin D2 promoter in a Myc-responsive E-box enhancer
elements dependent manner (Awasthi et al., 2005). In addition,
p30II colocalizes withMyc-TIP60 complexes in cultured HTLV-
1-infected ATL patient lymphocytes and enhances cyclin D2
promoter-driven transcription in a manner that requires TIP60
histone acetyltransferase (HAT) activity (Awasthi et al., 2005).
p30II also appears to modulate LTR-mediated transcription, in
the context of the entire provirus, at the post-transcriptional
level, by retaining Tax/Rex mRNA in the nucleus (Nicot et al.,
2004; Younis et al., 2004, 2006). Therefore, p30II acts as a
multifunctional protein with transcriptional and post-transcrip-
tional role in regulating viral gene expression and modulates the
transcriptional control of the cell cycle.
We have demonstrated that p30II colocalizes with p300 in the
nucleus and physically interacts with CBP/p300, at the highly
conserved KIX domain (Zhang et al., 2001). CBP/p300, an
important coactivator of cellular and viral transcription, issiently transfected HeLa-Tat cells. HeLa-Tat cells were seeded in two chamber
, and cotransfected with 4 μg of pME-p30II-HA and 2 μg of pCMV-p300 using
re fixed for 15 min using 4% paraformaldehyde. Cells were then incubated with
ated anti-p300 antibody (diluted 1:1000; Molecular probes) overnight at 4 °C.
loidin, while panel D represents nuclei staining using Hoechst 33342 stain. The
cal microscope (40×) and the images were merged using Adobe photoshop (E).
Fig. 2. Amino acids 1–132 of HTLV-1 p30II are critical for its physical
interaction with p300. (A) Schematic diagram of the known/putative functional
domains of p30II. Schematic diagram of the carboxyl terminal and amino
terminal deletion mutants of p30II is indicated. Bipartite NLS indicates the
nuclear localization sequence. Regions with sequence homology to the DNA
binding domain and homeodomain of Oct-1 are indicated. The numbers on both
sides of p30II indicate length of the peptide as number of amino acids. Letters
within the boxes indicate amino acids in p30II and Oct-1. (B) Top panel
represents the immunoprecipitation of p300 with p30II and serial deletion
mutants of p30II. Physical binding between various deletion mutants of p30II and
p300 was tested by expressing pCMV-p300 and pME-p30IIHA wild type or
serial deletion mutant plasmids in 293T cells, p300 pull-down from the cellular
lysates using polyclonal anti-HA antibody, followed Western immunoblot assay
with anti-p300 antibody. Below each line, the binding is indicated, as density of
each band measured by Gel-pro Analyzer software (middle panel). The results
above are representative of three experiments. The protein expression of the
carboxyl terminal and amino terminal deletion mutants of p30II was tested using
monoclonal anti-HA antibody (lower panel).
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causing an environment for competition between coactivators
and transcription factors, and providing additional regulation of
gene expression (Petrij et al., 1995; Suzuki et al., 1999). CBP
and p300 bridge transcription factors to relevant promoters and
through its intrinsic histone acetyl transferase (HAT) activity,
acetylates lysine residues at the amino terminus of histones. This
results in modification of chromatin structure to allow access of
the transcriptional machinery. p300 also directly acetylates
transcription factors such as p53 and GATA-1 and thus augment
their sequence-specific DNA-binding activity (Sterner and
Berger, 2000). Additionally, CBP/p300 is known to form
complexes with proteins such as p300/CBP-associated factor
(P/CAF), which also exhibits HAT activity (Grunstein, 1997).
HTLV-1 Tax associates with the LTR through its interaction with
CREB. These Tax-CREB promoter complexes act as a high-
affinity binding site to recruit multifunctional cellular coactiva-
tors CBP, p300 and P/CAF to activate the expression of viral
genes from the viral promoter (Lemasson et al., 2002).
Interestingly, p30II contains six highly conserved lysine
residues, four of which are part of the consensus acetylation
sequence (G/SK motif) (Bannister and Miska, 2000), and thus
represent potential acetylation sites for CBP/p300. Based on
this, we hypothesized that the intrinsic HAT activity of CBP/
p300 is utilized to acetylate and potentially modulate the
transcriptional regulatory function of p30II. There is also
evidence of a functional antagonistic relationship between
transcription factors, as a result of competition for binding to
common regions of CBP/p300 (Bannister and Kouzarides,
1995; Colgin and Nyborg, 1998; Kamei et al., 1996).
Interestingly, p30II disrupts CREB-Tax-CBP/p300 complexes
bound to the TRE repeats (Zhang et al., 2001).
Herein, we have identified motifs within p30II that are
important in binding CBP/p300 and in regulating LTR-
mediated transcription. Using N and C terminal deletion
mutants of p30II, we identified binding regions of p300 in
p30II and those important in regulating LTR-mediated tran-
scription in the context of the provirus. We also have identified,
using site-directed mutagenesis, a lysine residue at amino acid
position 106 (K3) of p30II that is critical for its repression of
TRE-mediated transcription. Exogenously expressed p300
rescued p30II-mediated repression on LTR-driven gene tran-
scription, irrespective of the presence or absence of the provirus.
p300 HAT mutants did not rescue p30II-mediated LTR
repression compared to wild type p300. The deacetylating
enzyme histone deacetylase-1 (HDAC-1) enhanced p30II-
mediated HTLV-1 LTR repression. Moreover, inhibition of
deacetylation by trichostatin A decreased p30II-mediated
HTLV-1 LTR repression. Our data confirm the role of p30II as
a regulator viral gene transcription, in association with p300.
This is the first report that identifies the functional domains of
HTLV-1 p30II important for binding CBP/p300 and in
regulating LTR-mediated transcription. Furthermore, our data
indicate that p30II opposes Tax-mediated LTR transactivation,
while Tax rescues p30II-mediated repression of LTR-driven
transcription, indicating the ability of these proteins to compete
with each other in modulating viral transcriptional activity.Results
HTLV-1 p30II accumulates with p300 in the nucleus
HTLV-1 p30II contains a nuclear localization signal,
characteristic of most proteins that function as a transcription
factor. Using immunofluorescence and immunoblot methods,
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the nucleus of transfected cells (Koralnik et al., 1993; Zhang et
al., 2000). To examine the subcellular localization of p30II, we
performed confocal microscopy on HeLa-Tat cells transiently
cotransfected with pMEp30IIHA. We used Alexa Fluor 633
phalloidin to stain cytokeratin in p30II expression cells (Fig. 1A)
and Hoechst staining as a nuclear marker (Fig. 1D). Consistent
with previous reports, p30II was detected predominantly in the
nucleus of our transiently transfected HeLa-Tat cells by
confocal microscopy (Fig. 1B). To test whether p30II compart-
mentally accumulates with p300 in the nucleus, we performed
confocal microscopy of HeLa-Tat cells transiently transfected
with pME p30IIHA and pCMV-p300, and verified the
subcellular localization of p30II (Fig. 1B) and p300 (Fig. 1C).
Merged images indicated that p30II-HA accumulated with p300
in the nucleus of cells that expressed both proteins (Fig. 1E).
HTLV-1 p30II physically interacts with p300 with enhanced
binding with aa 1–132
HTLV-1 p30II contains a bipartite nuclear localization
sequence and regions with sequence homology to the DNA
binding domain and homeodomain of transcription factors such
as Oct-1 (Fig. 2A). To test if p30II physically interacts with the
cellular transcriptional coactivator p300, we transiently trans-
fected 293T cells with pCMV-p300 and pME p30IIHA plasmidFig. 3. Subcellular localization of p30II serial deletion mutants. p30II in transiently
(Fisher Scientific) at approximately 50% confluence 18 h prior to transfection, and
Superfect (Gibco BRL). At 48 h post-transfection, media were removed and cells we
FITC conjugated anti-HA antibody (diluted 1:1000; Santa Cruz) overnight at 4 °C. C
acid domains present in each mutant are indicated. The expression of p30II-HAwas ev
minimum of triplicate experiments.encoding full-length p30II, prepared whole-cell extracts, and
performed coimmunoprecipitation assays. Our data indicated
that p300 was immunoprecipitated as a complex with p30II (Fig.
2B). In contrast, p300 could not be detected in the complexes
precipitated using preimmune serum while p30IIHA was
detected from the cellular lysate (data not shown).
To identify the regions of p30II that retain the ability to bind
p300, we performed transient cotransfection of 293T cells with
pCMV-p300 and various amino-terminal and carboxyl-terminal
serial deletion mutants of p30II, and whole-cell extracts were
used for coimmunoprecipitation assays (Fig. 2A). Each of the
p30II mutant proteins was expressed at the expected molecular
weight, as indicated by immunoblot analysis (Fig. 2B). The
subcellular localization characteristics of these mutants were
tested by confocal microscopy. Consistent with the presence or
absence of the bipartite nuclear localization signal (aa 73–78
and aa 91–98), mutant constructs expressing amino acids 1–
220, 1–179, 1–132, or 71–220 localized to the nucleus while
mutants containing amino acids 1–71, 100–179, and 179–241
localized to the cytoplasm (Fig. 3). As seen in Fig. 2B, our
binding data indicated enhanced binding of mutant representing
aa 1–132 of p30II, while mutants 1–220 and 1–179 also bound
p300 more intensely compared to the wild type p30II. Mutants
representing aa 1–71 and aa 71–220 had lower binding
compared to wild type p30II, whereas mutants 100–179 and
179–241 had slightly reduced or similar p300 binding as wildtransfected HeLa-Tat cells. HeLa-Tat cells were seeded in two chamber slides
cotransfected with 4 μg of each pME-p30II-HA serial deletion mutant using
re fixed for 15 min using 4% paraformaldehyde. Cells were then incubated with
ytokeratin staining of the cells was performed using anti-Phalloidin. The amino
aluated using Zeiss LSM 510 confocal microscope (40×). The results represent a
229B. Michael et al. / Virology 354 (2006) 225–239type p30II. Together, these results suggested that the nuclear
localization sequence favored p300 binding, but it was not
required for p30II to bind p300. These data are consistent the
known property of p300, which traffics between the cytoplasm
and nucleus, but accumulates primarily in the nuclear
compartment.
HTLV-1 p30II modulates HTLV-1 LTR-driven transcription
To test the effect of p30II on LTR-mediated transcription, we
transiently transfected increasing concentrations of pME
p30IIHA plasmid with constant amounts of our LTR-luc
reporter plasmid and tested for luciferase reporter activity. We
found that lower concentrations of the p30II plasmid (below
0.6 μg) consistently activated the HTLV-1 LTR reporter gene
activity, but increased amounts (above 0.6 μg) of the plasmid
repressed LTR reporter gene activity (Fig. 4A). Consistent with
our previous report (Zhang et al., 2000) and recent findings of
Awasthi et al. (2005), these data confirm that, at low
concentrations, p30II has the potential to enhance transcription,
while at higher doses p30II represses transcription.Fig. 4. HTLV-1 p30II differentially modulates LTR-mediated transcription in the
absence or the presence of the provirus. (A) In the absence of the provirus, p30II
enhances LTR-mediated transcription at low concentrations (up to 0.6 μg) and
represses LTR-mediated transcription at higher doses (above 0.6 μg). (B) In the
presence of full-length provirus, p30II represses LTR-mediated transcription in a
dose responsive fashion. 293Tcells were transiently cotransfected with 0.3 μg of
pLTR-luciferase reporter plasmid, increasing amounts of pME-p30II HA, and
±0.4 μg of ACH.30 proviral plasmid and the luciferase activity was measured.
Results represent the mean of optimized luciferase activity in arbitrary light units
(ALU) with standard error (SE) from a minimum of triplicate experiments.
Statistical analysis was performed using Student's t test. *Indicates P<0.05.We then tested the ability of p30II to regulate LTR-mediated
transcription in the presence of the HTLV-1 provirus. By
transiently transfecting pME-p30IIHA at various doses with
ACH.30, provirus deleted for p30II expression, we have found
that p30II represses LTR-mediated transcription, in a dose
responsive fashion (Fig. 4B). Interestingly, at concentrations
that activated LTR-mediated transcription in the absence of
ACH.30 (below 0.6 μg), we found that p30II indeed represses
LTR-mediated transcription if the provirus is present.
p300 rescues p30II-dependent repression of LTR-driven
transcription
HTLV-1 Tax-mediated transactivation is dependent, in part,
on the coadaptors CBP/p300. Tax binds p300 at the KIX
domain similar to p30II. Our previous reports suggested that
p30II and Tax serve apposing roles in the regulation of LTR-
mediated transcription. Based on the hypothesis that p30II
represses LTR-driven reporter gene activities via competition
for limited basal quantities of CBP/p300, we tested if
overexpressing p300 rescues p30II-mediated repression of
LTR-driven reporter gene expression. By transiently transfect-
ing increasing concentrations of pCMV-p300 with constant
amounts of pME-p30IIHA plasmid, our data indicated that p300
expression rescues the p30II-dependent repression of LTR-
luciferase reporter gene activity (Fig. 5A).
To test if the p30II-mediated repression of LTR-mediated
transcription in the presence of the HTLV-1 provirus, is
influenced by p300, we transiently transfected increasing
amounts of pCMV-p300 with constant amounts of pME-
p30IIHA and ACH.30, a provirus that lacks wild type p30II
expression (Robek et al., 1998). Interestingly, even in the
presence of the provirus, increasing doses of p300 reversed the
ability of p30II to repress the LTR-mediated transcription, in a
dose responsive fashion (Fig. 5B). Taken together, these data
indicated that p300 has the ability to modulate the transcrip-
tional regulatory function of p30II on the LTR.
HTLV-1 p30II competes with Tax in LTR-driven transcription
Since p30II and Tax bind CBP/p300 at the KIX domain and
since the transcriptional regulatory functions of p30II and Tax
on the LTR are influenced by p300, we hypothesized that Tax
and p30II might competitively influence the transcriptional
regulatory function of each other on the HTLV-1 LTR. To test
the effect of p30II on Tax-mediated LTR transactivation, we
transiently cotransfected increasing concentrations of pME
p30IIHA plasmid with constant concentration of LTR-luc
reporter plasmid, as well as pCMV-Tax plasmid and tested the
luc reporter activity. We found that p30II consistently repressed
the Tax transactivation of the HTLV-1 LTR reporter gene
activity, in a dose-dependent manner (Fig. 6A). Conversely, to
test the effect of HTLV-1 Tax on p30II-mediated repression of
the LTR transcriptional activity, we transiently cotransfected
increasing concentrations of pCMV-Tax plasmid along with
constant concentration of LTR-luc reporter plasmid as well as
pME p30IIHA plasmid and tested the luc reporter activity. We
Fig. 6. HTLV-1 p30II and Tax appear to compete with each other in modulating
the LTR-mediated transcription. (A) p30II represses Tax-mediated LTR
transactivation in a dose-dependent manner. (B) Tax rescues p30II-mediated
repression of LTR-driven transcription in a dose-dependent fashion. 293T cells
were transiently cotransfected with 0.3 μg of pLTR-luciferase reporter plasmid
along with either 0.4 μg of pCMV-Tax plasmid and increasing quantities of
pME-p30II HA (Fig. 6A) or 1.2 μg of pME-p30II HA plasmid and increasing
quantities of pCMV-Tax (Fig. 6B). pME 18S (Fig. 6A) or a plasmid containing
CMV promoter (Fig. 6B) was used as carrier DNA to equalize DNA
concentrations for each transfection. Results represent the mean of optimized
luciferase activity in arbitrary light units (ALU) with standard error (SE) from a
minimum of triplicate experiments. Statistical analysis was performed using
Student's t test. *Indicates P<0.05.
Fig. 5. p300 expression reverses the p30II-dependent repression of LTR-driven
transcription, in the absence or the presence of the provirus. (A) In the absence of
the provirus, p300 expression reverses the p30II-dependent repression of LTR-
driven transcription, in a dose-responsive manner. (B) p300 reverses the p30II-
dependent repression of LTR-driven transcription, in the presence of the
provirus, in a dose-responsive manner. 293T cells were transiently cotransfected
with 0.3 μg of pLTR-luciferase reporter plasmid, 1.2 μg pME-p30II-HA,
increasing quantities of pCMV-p300, and ±0.4 μg of ACH.30 proviral plasmid
and the luciferase activity was measured. Results represent the mean of
optimized luciferase activity in arbitrary light units (ALU) with standard error
(SE) from a minimum of triplicate experiments. Statistical analysis was
performed using Student's t test. *Indicates P<0.05.
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sion of the LTR reporter gene activity, in a dose-dependent
manner (Fig. 6B).
HTLV-1 p30II domains important for its repression of
LTR-driven transcription
To identify the regions of p30II required for repression of
LTR-driven transcription, 293T cells were transiently cotrans-
fected with a series of carboxyl-terminal and amino-terminal
truncation mutants of p30II and our LTR-luciferase reporter
plasmid, and then tested for their ability to reduce the LTR-
luciferase activity. The luciferase activity elicited by LTR-
luciferase construct, in the presence of the full-length p30II was
compared to luciferase activity in the presence of each of the
serial deletion mutants (Fig. 7A). Luciferase activity elicited by
the serially deleted mutants 1–220, 1–179, 1–132, and 1–71
were higher than that by the full-length p30II, while in thepresence of mutants 179–241, 100–179, and 71–220, the
luciferase activity was less than that in the presence of the wild
type p30II. Together, these data indicated that the region
between 71 and 220 is able to repress the LTR-luc reporter to a
greater degree than wild type p30II, suggesting that these amino
acid sequences are important for the repression of LTR-driven
transcription by p30II. Interestingly, mutants representing aa
1–220, aa 1–179, and aa 1–132 abolished the ability of p30II
to repress LTR-driven reporter activity, which suggests the
carboxyl region of the protein contains domain(s) that modify
the transcriptional repressive function of p30II. The mutant
representing aa 1–71, while lacking the bipartite nuclear
localization domain, retained some repressive activity, indicate
that nuclear accumulation is not a strict requirement for this
activity.
Based on our serial deletion mutant data, we cannot rule out
the possibility of a change in the physical conformation or other
properties of the mutant proteins (e.g., altered post translation
modifications), causing the observed differences in their
Fig. 7. Amino acids 100–179 of p30II are critical for its repression of LTR-
driven transcription, in the absence or the presence of the provirus. (A) In the
absence of the provirus, amino acids 100–179 of p30II are critical for its
repression of LTR-driven transcription. (B) In the presence of the provirus,
amino acids 100–179 of p30II are critical for its repression of LTR-driven
transcription. 293T cells were transiently cotransfected with 0.3 μg of pLTR-
luciferase reporter plasmid, 1.2 μg pME-p30II-HA wild-type or serial deletion
mutants, and ±0.4 μg of ACH.30 proviral plasmid and the luciferase activity
was measured. Results represent the mean of optimized luciferase activity in
arbitrary light units (ALU) with standard error (SE) from a minimum of triplicate
experiments. Statistical analysis was performed using Student's t test. *Indicates
P<0.05.
Table 1
Lysine residues in p30II are conserved among various HTLV-1 isolates
Lysine residue and amino
acid position within p30II
Percentage
conservation a
K1 (50) 87.5
K2 (103) 66.7
K3 (106) 87.5
K4 (123) 87.5
K5 (143) 91.7
K6 (152) 91.7
a p30II amino acid sequences were compared using data available from public
databases and compared using commercial software (Vector NTI, AlignX).
231B. Michael et al. / Virology 354 (2006) 225–239transcriptional activity. These data, however, suggest that the
amino acid sequences from 71–220 of p30II are important for
its function as a repressor of LTR-mediated transcription. The
mutant containing amino acid sequence 100–179 was also able
to repress LTR-mediated transcription at levels similar to that
of 71–220. The differences in activity between these mutant
were not statistically significant (P<0.15), and therefore, the
amino acids 71–179 appear to be the structural motif within
p30II, important for its repression of LTR-mediated reporter
activity.
To determine which of our serial deletion mutants of p30II
retained the ability to repress LTR-mediated transcription in the
presence of the provirus, we performed transient transfection of
293T cells with ACH.30 proviral clone, LTR-luc, and the
carboxyl-terminal and amino-terminal truncation mutants of
p30II and measured the luciferase activity (Fig. 7B). While most
mutants retained repressive activity, those that lacked the
carboxyl end of the p30II (1–220 and 1–179) were more limited
in their ability to repress LTR reporter gene activity in the
presence of the provirus and mutant 100–179 retained the
greatest amount of repressive ability. Taken together, these data
indicate that the amino acid sequence 100–179 of p30II is
critical in repression of LTR-mediated transcription in the
presence or absence of the HTLV-1 provirus.Lysine 106 (K3) of HTLV-1 p30II influences repression of
LTR-driven transcription
HTLV-1 p30II contains six lysine residues (K1–K6) (Table
1). Interestingly, five of these are within the domain comprised
of amino acids 100–179. Importantly, four (K2–K5) of the
lysine residues within this domain are part of a consensus
acetylation sequence (G/SK motif) (Bannister and Miska,
2000). To determine the role of these lysine residues in p30II-
mediated repression of LTR-driven transcription, 293T cells
were transiently cotransfected with arginine substitution
mutants for each lysine residue of p30II and tested for their
ability to repress LTR-luciferase reporter gene activity (Fig.
8A). Luciferase activity elicited by the arginine substitution
mutant K3 (amino acid 106) was higher than that by the full-
length p30II and each of the other lysine mutants (K2, K4, and
K5) and the pME empty plasmid. These data indicated that the
lysine at amino acid position 106 of p30II is important for its
ability to repress LTR-luc reporter gene activity.
To determine the role of these lysine residues in p30II-
mediated repression of LTR-driven transcription, in the
presence of the provirus, we performed transient transfection
of 293T cells with ACH.30, LTR-luc, and each of the arginine
substitution mutants of p30II and measured luciferase activity
(Fig. 8B). Similar to our data using only the LTR reporter gene,
the arginine substitution mutant K3 (amino acid 106)
significantly altered, but did not eliminate the ability of wild
type p30II to mediated repression. Taken together, these data
indicate that the lysine residue at amino acid position 106 of
p30II is important for its function as a repressor of LTR-
mediated transcription.
Histone acetyltransferase (HAT) activity of p300 modulates
p30II-dependent repression of LTR-driven transcription
Our findings that the lysine residue at amino acid position
106 (K3) of p30II was important for repressing TRE-mediated
transcription, suggested a potential role of post translation
modification of the viral protein, perhaps through acetylation, in
p30II-mediated LTR repression. To test the role of p300 HAT
domain on p30II-dependent repression of LTR-driven transcrip-
tion, we transiently cotransfected pME-p30IIHA and an LTR-
luciferase reporter plasmid, along with either wild type or p300
HAT mutant plasmids. In contrast to the wild type p300, p300
Fig. 8. Lysine 106 (K3) of p30II is critical for its repression of LTR-driven
transcription in the absence or the presence of the provirus. (A) In the absence of
the provirus, lysine 106 (K3) of p30II is critical for its repression of LTR-driven
transcription. (B) In the presence of the provirus, lysine 106 (K3) of p30II is
critical for its repression of LTR-driven transcription. 293Tcells were transiently
cotransfected with 0.3 μg of pLTR-luciferase reporter plasmid, 1.2 μg pME-
p30II-HA wild-type or site directed mutants, and ±0.4 μg of ACH.30 proviral
plasmid and the luciferase activity was measured. Results represent the mean of
optimized luciferase activity in arbitrary light units (ALU) with standard error
(SE) from a minimum of triplicate experiments. Statistical analysis was per-
formed using Student's t test. *Indicates P<0.05.
Fig. 9. p300 HAT mutants only partially rescue p30II-dependent repression of
LTR-driven transcription in the absence of the provirus (A) or the presence of the
provirus (B). 293T cells were transiently cotransfected with 0.3 μg of pLTR-
luciferase reporter plasmid, 1.2 μg pME-p30II HA, 2.4 μg of either the wild type
p300 plasmid or one of the p300 HAT mutant plasmids, M3 or M7, and ±0.4 μg
of ACH.30 proviral plasmid and the luciferase activity was measured. A plasmid
containing CMV promoter was used as carrier DNA to equalize DNA
concentrations for each transfection. Results represent the mean of optimized
luciferase activity in arbitrary light units (ALU) with standard error (SE) from a
minimum of triplicate experiments. Statistical analysis was performed,
comparing to the values obtained in the presence of p30II and CMV empty
plasmid, using Student's t test. *Indicates P<0.05.
232 B. Michael et al. / Virology 354 (2006) 225–239HAT mutants only partially rescued the p30II-dependent
repression of LTR-luciferase reporter gene activity (Fig. 9A).
We then tested the role of histone acetyltransferase activity
mediated by p300 plasmids on p30II-dependent repression of
LTR-driven transcription, in the presence of the HTLV-1
provirus. We transiently cotransfected pME-p30IIHA, LTR-luc
reporter plasmid, and ACH.30, a provirus deleted for p30II
expression, along with either wild type or HATmutants of p300,
and tested the luciferase reporter activity. Interestingly, p300
HAT mutant plasmids failed to rescue p30II-dependent repres-
sion of LTR-luciferase reporter gene activity, compared to the
wild type p300 plasmid, in the presence of the HTLV-1 provirus
as well (Fig. 9B). These data confirm that the HTLV-1 LTR
transcriptional regulatory effect of p30II is influenced by the
HAT activity of p300.
Deacetylation by HDAC-1 enhances p30II-dependent
repression of HTLV-1 LTR-driven transcription
Histone acetyl transferases and histone deacetylases
(HDACs) form multiprotein complexes with transcriptional
factors and are known to regulate their transcriptional activity(Ego et al., 2002). In addition, HDAC-1 is known to physically
and functionally interact with Tax and repress the LTR
transactivation function of Tax (Ego et al., 2002). To test if
deacetylation by HDAC-1 has a similar role on p30II-dependent
repression of LTR-mediated transcription, we transiently
cotransfected increasing concentrations of HDAC-1 plasmid
with constant concentration of pME-p30IIHA plasmid and LTR-
luciferase reporter plasmid and tested the luciferase reporter
activity. Our data indicated that HDAC-1 expression enhanced
p30II-dependent repression of LTR-luciferase reporter gene
activity, in a dose-dependent manner (Fig. 10A).
We then tested the role of deacetylation on p30II-dependent
repression of LTR-mediated transcription, in the presence of the
HTLV-1 provirus, by transiently cotransfecting increasing
concentrations of the HDAC-1 plasmid with constant concen-
tration of pME-p30IIHA plasmid, LTR-luciferase reporter
plasmid, and ACH.30, a provirus deleted for p30II expression.
Our data indicated that addition of HDAC-1 enhanced p30II-
dependent repression of LTR-luciferase reporter gene activity,
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(Fig. 10B). These data further support our findings that the
HTLV-1 LTR transcriptional modulatory function of p30II is
dependent on deacetylation by HDAC-1.
Acetylation by trichostatin A (TSA) decreases p30II-dependent
repression of HTLV-1 LTR-driven transcription
Reversible modification of the core histones is crucial in the
regulation of gene expression. While histone acetylation is
typically associated with nucleosomal decondensation neces-
sary for transcriptional activation, histone deacetylation is
associated with nucleosomal condensation and subsequent
transcriptional repression (Ego et al., 2002). Repression of
Tax transactivation of HTLV-1 LTR by HDAC-1 can be restored
when treated with an HDAC inhibitor, namely, trichostatin A
(Ego et al., 2002). Similarly, we tested the effect of inhibition of
deacetylation on p30II-dependent repression of LTR-mediatedFig. 10. Addition of HDAC-1 enhances p30II-dependent repression of HTLV-1
LTR-driven transcription in the absence of the provirus (A) or the presence of the
provirus (B). 293T cells were transiently cotransfected with 0.3 μg of pLTR-
luciferase reporter plasmid, 1.2 μg pME-p30II HA, 0.0, 0.5, 1.0, or 1.5 μg
HDAC-1 plasmid, and ±0.4 μg of ACH.30 proviral plasmid and the luciferase
activity was measured. A plasmid containing the same promoter as the HDAC-1
plasmid was used as carrier DNA to equalize DNA concentrations for each
transfection. Results represent the mean of optimized luciferase activity in
arbitrary light units (ALU) with standard error (SE) from a minimum of triplicate
experiments. Statistical analysis was performed, comparing to the values
obtained in the presence of p30II and no HDAC-1 plasmid, using Student's t
test. *Indicates P<0.05.transcription. To determine the most effective concentration of
TSA, we transiently cotransfected 293T cells with 1.0 μg of
HDAC-1 plasmid, 1.2 μg of pME-p30IIHA plasmid, and 0.3 μg
of LTR-luciferase reporter plasmid, and added either 0.0, 100,
200, or 400 nM TSA at 24 h post-transfection (Fig. 11A). The
most effective dose of TSA was determined in a dose titration
experiment to be 100 nM. Higher concentrations of TSA likely
were not as effective due to cell toxicity. We then tested the
luciferase reporter activity at 48 h post-transfection and
compared the difference in luciferase activity in the presence
of various concentrations of TSA and found that 100 nM TSA
had the highest effect in decreasing p30II-dependent LTR
repression (data not shown). Next, to determine the effect of
TSA at different concentrations of HDAC-1, we transiently
cotransfected 293T cells with increasing concentrations of a
HDAC-1 plasmid with constant concentration of pME-p30IIHA
plasmid and LTR-luciferase reporter plasmid, and added
100 nM TSA at 24 h post-transfection. We then tested the
luciferase reporter activity at 48 h post-transfection and
compared the difference in luciferase activity in the presence
or absence of TSA. Our data demonstrated that TSA, an
inhibitor of deacetylation, decreases p30II-dependent repression
of LTR-luciferase reporter gene activity, at various doses of
HDAC-1, in the absence of the provirus (Fig. 11B).
We then tested the role of inhibition of deacetylation on
p30II-dependent repression of LTR-mediated transcription, in
the presence of the HTLV-1 provirus, by transiently cotransfect-
ing increasing concentrations of HDAC-1 plasmid with
constant concentration of pME-p30IIHA plasmid, LTR-lucifer-
ase reporter plasmid, and ACH.30, a provirus deleted for p30II
expression and by adding 100 nM TSA at 24 h post-
transfection. We then tested the luciferase reporter activity at
48 h post-transfection and compared the difference in luciferase
activity in the presence or absence of TSA. Interestingly,
addition of TSA decreased p30II-dependent repression of LTR-
luciferase reporter gene activity, at various concentrations of
HDAC-1, in the presence of the provirus as well (Fig. 11C).
These data further implicated that the HTLV-1 LTR transcrip-
tional regulatory effect of p30II is dependent on deacetylation
by HDAC-1 and inhibition of deacetylation by TSA.
P/CAF does not rescue p30II-dependent repression of HTLV-1
LTR-driven transcription
P/CAF is an important coactivator that mediates transcrip-
tion through HAT activity (Sterner and Berger, 2000). P/CAF
acetylates various nonhistone transcription-related proteins,
such as the chromatin proteins HMG17 and HMG I(Y),
activators p53, MyoD, human immunodeficiency virus (HIV)
Tat, and general transcription factors TFIIE and TFIIF (Sterner
and Berger, 2000). In addition, P/CAF is recruited to the Tax
responsive element sites on the HTLV-1 LTR, through direct
interaction with Tax and enhance Tax-mediated HTLV-1
transcription, in a HAT-independent manner (Jiang et al.,
1999). We therefore tested if P/CAF has a role on p30II-
dependent repression of HTLV-1 LTR-driven transcription. We
transiently cotransfected increasing concentrations of P/CAF
Fig. 12. Expression of P/CAF does not rescue p30II-dependent repression of
HTLV-1 LTR-driven transcription. 293T cells were transiently cotransfected
with 0.3 μg of pLTR-luciferase reporter plasmid, 1.2 μg pME-p30II HA and 0.0,
0.6, 1.2, or 2.4 μg wild type P/CAF, or 2.4 μg P/CAF HAT mutant plasmid, and
the luciferase activity was measured. A plasmid containing the same promoter as
the P/CAF plasmids (CMV promoter) was used as carrier DNA to equalize DNA
concentrations for each transfection. Results represent the mean of optimized
luciferase activity in arbitrary light units (ALU) with standard error (SE) from
a minimum of triplicate experiments. Statistical analysis was performed, com-
paring to the values obtained in the presence of p30II alone, using Student's t
test. Statistical significance was also performed, to compare between pCAF wild
type and HAT mutant, using Student's t test. *Indicates P<0.05.
Fig. 11. Addition of 100 nM Trichostatin A (TSA) counteracts enhancement of
p30II-dependent repression of HTLV-1 LTR-driven transcription by HDAC-1.
(A) To determine effective concentration of TSA, 293T cells were cotransfected
with 1.0 μg of HDAC-1 plasmid, 1.2 μg of pME-p30IIHA plasmid, and 0.3 μg of
LTR-luciferase reporter plasmid, with either 0.0, 100, 200, or 400 nM TSA
added to culture media at 24 h post-transfection and the luciferase activity
measured. (B and C) Addition of TSA counteracts the enhancement of p30II-
dependent repression of HTLV-1 LTR-driven transcription by HDAC-1 in the
absence (B) or the presence of the provirus (C). 293T cells were transiently
cotransfected with 0.3 μg of pLTR-luciferase reporter plasmid, 1.2 μg pME-
p30II HA, 0.0, 0.5, 1.0 or 1.5 μg HDAC-1 plasmid, and ±0.4 μg of ACH.30
proviral plasmid. A plasmid containing the same promoter as the HDAC-1
plasmid was used as carrier DNA to equalize DNA concentrations for each
transfection. At 24 h post-transfection, 100 nM TSA (Sigma) was added to the
culture medium, when specified, and the luciferase activity was measured.
Results represent the mean of optimized luciferase activity in arbitrary light units
(ALU) with standard error (SE) from a minimum of triplicate experiments.
Statistical analysis was performed, comparing between values obtained in the
presence or absence of TSA, at the same concentration of HDAC-1, using
Student's t test. *Indicates P<0.05.
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and LTR-luc reporter plasmid and tested the luciferase reporter
activity. Our data indicated that, unlike p300, P/CAF does not
rescue p30II-dependent repression of HTLV-1 LTR-driven
transcription (Fig. 12). In addition, to test if the HAT activity
of P/CAF influences p30II-dependent repression of HTLV-1
LTR-driven transcription, we transiently cotransfected pME-
p30IIHA plasmid and LTR-luc reporter plasmid along with
either wild type P/CAF plasmid or P/CAF HAT mutant plasmid,
and tested the luc reporter activity. We found that the P/CAF
HAT mutant did not significantly alter p30II-dependent
repression of HTLV-1 LTR-driven transcription, compared to
wild type P/CAF (Fig. 12). These data confirm that the HTLV-1
LTR transcriptional regulatory effect of p30II is p300-dependent
and not P/CAF-dependent.
Discussion
Our data are the first to identify functional motifs of p30II
that are critical in binding p300 and in repressing LTR-mediated
transcription. Identification of these motifs is important for
defining the molecular mechanism of p30II-mediated repression
of LTR-driven transcription. We found that the region important
for binding p300 is amino acid sequence 1–132, while the motif
that plays a major role in repressing LTR-mediated transcription
is amino acid sequence 100–179, which contains the entire
DNA binding region, part of the homeodomain with homology
to Oct-1 and POU family of transcription factors as well as 5
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acetylation sequence (Bannister and Miska, 2000) representing
potential acetylation sites for CBP/p300. The lysine residue at
amino acid position 106 (K3) of HTLV-1 p30II was important
for p30II-mediated repression of LTR-driven transcription in the
presence or absence of the provirus. Our data using p300 HAT
mutants demonstrated that the histone acetyl transferase domain
of p300 influences HTLV-1 LTR-mediated transcription by
p30II. These data were further supported by experiments that
indicated that p30II LTR repression was enhanced on
deacetylation by HDAC-1 and inhibited by TSA, an inhibitor
of HDAC-1.
The coactivators CREB binding protein (CBP) and p300
mediate transcriptional control of various cellular and viral
DNA binding transcription factors. Although these coactivators
have divergent functions, they are similar in nucleotide
sequence, are evolutionarily conserved, and are commonly
referred to as CBP/p300 (Blobel, 2000; Goodman and Smolik,
2000). CBP and p300 are highly related and share many
functional properties; however, there is evidence that these
factors are not interchangeable (Vo and Goodman, 2001).
Several cellular and viral proteins that interact with either CBP
or p300 have been identified, including steroid and retinoid
hormone receptors, CREB, c-Jun, c-Myb, Sap-1a, c-Fos,
MyoD, p53, Stat-1/2, NF-κB, pp90rsk, TATA-binding protein,
TFIIB (Avantaggiati et al., 1997; Goodman and Smolik, 2000;
Janknecht and Hunter, 1996a, 1996b), HTLV-1 Tax, adenovirus
E1A, Kaposi's sarcoma-associated herpes virus viral interferon
regulatory factor protein, and simian virus 40 large T antigen
(Arany et al., 1995; Ariumi et al., 2000; Avantaggiati et al.,
1996; Colgin and Nyborg, 1998; Kashanchi et al., 1998; Kwok
et al., 1996; Suzuki et al., 1999).
CBP and p300 bridge transcription factors to relevant
promoters, have intrinsic histone acetyltransferase (HAT)
activity, and form complexes with proteins such as CBP/p300
binding protein-associated factor, which also exhibits HAT
activity (Grunstein, 1997). Recently, there is increasing knowl-
edge of the mechanism and functional significance of the
interactions between many viral proteins and CBP/p300. In the
case of adenovirus oncoprotein E1A, interaction with CBP/
p300 is critical for regulation of transcription, suppression of
differentiation, and immortalization of cells in culture (Arany et
al., 1995; Avantaggiati et al., 1996; Lundblad et al., 1995).
Simian virus T antigen regulates the expression of a group of
cellular genes by modifying the HAT activity of CBP/p300 or
by bridging the gap between DNA binding transcription factors
and components of the general transcription machinery
(Avantaggiati et al., 1997; Goodman and Smolik, 2000). p30II
has recently been demonstrate to increase the transforming
potential of Myc and transcriptionally activate the human cyclin
D2 promoter (Awasthi et al., 2005). The enhanced c-Myc
transforming activity by p30II was dependent upon the
transcriptional coactivators, transforming transcriptional acti-
vator protein/p434 and TIP60, and required TIP60 histone
acetyltransferase (HAT) activity. Similar to our findings,
Awasthi et al. (2005) demonstrated that aa 99 to 154 within
p30II were required for transcriptional regulation by TIP60.Therefore, identifying the molecular mechanism and functional
significance of HAT-dependent transcription will be important
to understanding of the role of p30II in lymphocyte transforma-
tion by HTLV-1 and replication of the virus in vivo.
Previously, using deletion mutants of CBP/p300 in GST
pull-down assays, we localized the binding site of CBP/p300 for
p30II to a highly conserved KIX region. Interestingly, KIX
domain is the binding site of CBP/p300 for HTLV-1 Tax protein
as well. In addition, p30II was able to disrupt CREB-Tax-CBP/
p300 complexes bound to the viral 21-bp TRE repeats (Zhang et
al., 2001). These results indicate that p30II might act in contrast
to the role of HTLV-1 Tax. The role of CBP and p300
coactivators in HTLV-1 gene expression has been the focus of
many previous reports. HTLV-1 Tax, a transactivator of LTR-
mediated transcription, is critical in the activation of the HTLV-
1 viral genes through its interaction with the p300 and CBP
coactivators (Bex and Gaynor, 1998).
Although CBP and p300 mediate the activities of various
transcription factors, many earlier reports prove that it is present
in the cell at limiting concentrations. Even small reductions in
the concentrations of these coactivators are damaging in many
instances, such as in the human Rubinstein–Taybi syndrome
where loss of a single CBP allele causes developmental defects
(Petrij et al., 1995). In experiments where transcription factors
are exogenously expressed, it is possible that the capacity of the
endogenous CBP/p300 is overridden and the effects due to
competition may be more obvious. Many such studies have
demonstrated the competition between different molecules for
CBP/p300. Even though some of these involve two mutually
antagonistic transcription factors with the same shared binding
site on CBP/p300, competition does not necessarily require
having the same binding site. In circumstances where CBP/
p300 levels are limiting, there could be selective preference of
one over the other, causing an exclusion of one of the proteins.
In our study, we found that HTLV-1 p30II and Tax appear to
compete with each other in modulating the transcriptional
activity from the LTR. Since HTLV-1 p30II and Tax interact
with CBP/p300 through the same KIX domain, we believe that
this is through competitive CBP/p300 binding between p30II
and Tax. Analogously, the binding of Tax and c-Myb to KIX
domain of CBP was found to be mutually exclusive and Tax
expression was shown to interfere with transcriptional activity
of c-Myb (Colgin and Nyborg, 1998).
An environment of coactivator competition between tran-
scription factors provides an additional layer of regulated gene
expression. The relative amounts of Tax and p30II may be
critical in determining which protein binds to CBP/p300 and the
consequent regulation of LTR-mediated transcription of viral
genes from the HTLV-1 viral promoter. When its levels are low,
p30II also enhances transcription from the viral promoter. Under
such circumstances, p30II and Tax might act synergistically.
However, at higher concentrations, p30II may antagonize Tax
transactivation of the HTLV-1 promoter. There are similar
reports on positive and negative effects by the same protein in
other viruses, such as herpes simplex virus type 1 (HSV-1), in
which the interaction between cellular and viral transcription
factors plays a critical role in the regulation of the immediate-
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from HSV-1, binds the host cell protein HCF, which facilitates
the stable complex formation of the viral protein with Oct-1
(Wilson et al., 1997). The IE gene promoter contains an Oct-1-
like motif (TAATGARAT) that is important for IE gene
expression, with both positive and negative effects, depending
on the context of these cellular transcription factors and VP16
(Thomas et al., 1998).
CBP and p300 bridge transcription factors to relevant
promoters and through its intrinsic histone acetyl transferase
(HAT) activity acetylates lysine residues at the amino terminus
of histones, which results in modification of chromatin structure
to allow access of the transcriptional machinery. CBP/p300 is
known to form complexes with proteins such as CBP/p300
binding protein-associated factor, which also exhibits HAT
activity (Grunstein, 1997). p300 also directly acetylate
transcription factors such as p53, GATA-1, and c-myb and
thus augment their sequence-specific DNA-binding activity
(Sterner and Berger, 2000). Simian virus T antigen regulates the
expression of a group of cellular genes by modifying the HAT
activity of CBP/p300 or by bridging the gap between DNA
binding transcription factors and components of the general
transcription machinery (Avantaggiati et al., 1997; Goodman
and Smolik, 2000). c-myb oncoprotein of the avian retrovirus
group is known to be acetylated by CBP/p300 at its multiple
lysine residues (Colgin and Nyborg, 1998).
p30II contains six highly conserved lysine residues, 5 of
which are within the amino acid region 100–179, four of which
are part of the consensus acetylation sequence (G/SK motif)
(Bannister and Miska, 2000) and thus represent potential
acetylation sites for CBP/p300 (Table. 1). We found that the
lysine residue at amino acid position 106 (K3) of HTLV-1 p30II
is critical for its repression of LTR-driven transcription in the
presence or absence of the provirus. We tested the expression
level of all the arginine substitution mutants for each of the
lysines (K2–K5) by Western immunoblot and found that the
expression of all the mutants was similar to that of the wild type
p30II (data not shown). Based on this, it is possible that the
intrinsic HAT activity of CBP/p300 is utilized to acetylate and
potentially modulates the transcriptional regulatory function of
p30II. Our ongoing studies seek to determine if p30II is directly
acetylated or post-translationally modified in other ways (e.g.,
phosphorylation) and if these potential modifications regulate
its function.
Recently, it was reported that p30II modulates LTR-mediated
transcription, in the context of the entire provirus, by a post-
transcriptional mechanism (Nicot et al., 2004; Younis et al.,
2004). Previous studies from our laboratory demonstrated that
HTLV-1 p30II directly interacts with CBP/p300 to modulate
gene transcription (Zhang et al., 2000, 2001). Data presented in
this report further confirm the role of CBP/p300 in the
modulation of LTR-mediated transcription by p30II, in the
context of the provirus. In the presence of increasing
concentrations of p300, there was a dose-dependent rescue of
LTR-driven gene transcription, irrespective of the presence or
absence of the provirus. Although, we cannot rule out the
possibility of a post-transcriptional mechanism by HTLV-1p30II, this report presents convincing evidence for a p300-
dependent transcriptional regulatory function. Therefore,
HTLV-1 p30II appears to be a multifunctional protein with
transcriptional and post-transcriptional role in regulating gene
expression.
As of yet, there is no much information regarding the relative
levels of various HTLV-1 proteins during various stages of the
infection. It is possible that differences in expression levels of
various viral proteins, leading to differences in transcriptional
regulation as described above might be the mechanism by
which HTLV-1 infection/disease progresses though various
stages (Princler et al., 2003). This is likely to be in synergy with
differential regulation of cellular gene regulation by Tax and/or
p30II and thus changing the immune responses in accordance
with different stages of progression of HTLV-1 infection and
disease. Our current data are supported by recent findings from
our laboratory where an infectious HTLV-1 molecular clone
failed to maintain viral loads in vivo when p30II expression was
abolished (Silverman et al., 2004). Taken together, our data
indicate that HTLV-1, a complex retrovirus associated with
lymphoproliferative disorders, uses accessory genes to promote
cell-to-cell transmission of the virus, clonal expansion of
infected cells, and maintenance of proviral loads in vivo.
Materials and methods
Cell lines
293T cells were obtained from G. Franchini (National
Cancer Institute, NIH, Bethesda) and HeLa-Tat cells were
obtained from AIDS Research and Reference Reagent Program,
National Institute of Health. 293T and HeLa-Tat cells were
grown in modified Dulbecco's eagle medium containing 10%
fetal bovine serum and 1% streptomycin and penicillin at 37 °C.
Cells were split and cultured in six-well plates, 10 cm dishes, or
chamber slides to 50–60% confluence 16–18 h before
transfection.
Plasmids
The pTRE-Luc plasmid and pRSV-B-Gal have been
described previously (Zhang et al., 2000, 2001). pME-
p30IIHA wild-type and serial deletion mutant plasmids were
created by cloning the p30II sequence from HTLV-1 molecular
clone, ACH with downstream influenza hemagglutinin (HA1)
tag, into pME-18S plasmid (G. Franchini, National Cancer
Institute) between 5′ EcoRI and 3′ NotI sites. Site-directed
mutants were made by substituting lysines in pMEp30IIHAwith
arginine. Fidelity of the plasmids was confirmed by Sanger
sequencing and p30II HA protein expression was confirmed by
Western blot using monoclonal anti-HA antibody (Covance,
Berkeley, CA). ACH.30 plasmid has a 24 bp insertion that
causes an artificial termination codon in p30II (Robek et al.,
1998). pCMV-Tax expresses the HTLV-1 Tax protein and has
been described previously (Newbound et al., 1996). pCMV-
p300 expresses the full-length p300 protein from a CMV I/E
promoter (Upstate USA, Inc., Charlottesville, VA). The HDAC-
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University, Cambridge, MA). Wild type and HAT mutants of
P/CAF have been described previously (Jiang et al., 1999).
Cell transfection and reporter gene assay
For each transfection, 0.3 μg of pTRE-Luc reporter plasmid
was cotransfected with pME-p30IIHA wild type or serial
deletion/arginine substitution mutant plasmids and 0.4 μg
ACH.30 plasmid when specified, using Lipofectamine Plus
(Invitrogen, Carlsbad, CA). When pCMV-p300 plasmid was
used, it was also cotransfected. As an internal control for
transfection efficiency, 0.1 μg of pRSV-(Gal (Invitrogen) was
also used in each transfection. pME 18S was used as carrier
DNA to equalize DNA concentrations for each transfection.
Transfected cells were lysed with 400 (l lysis buffer (Promega,
Madison, WI) per well for 25 min. Twenty microliters of each
lysate was used to test luciferase reporter gene activity using an
Enhanced (Luciferase Assay kit (Promega). To normalize
transfection efficiency, cells were washed with PBS, stained
with 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-
Gal) (Sigma, St. Louis, MO) and counted (Gal expressing cells
using 20× objective of light microscope. Cotransfection of
pME-p30IIHA had no effect on the X-Gal staining (data not
shown). Results were expressed as mean of optimized
luciferase activity (luciferase activity/percentage cells stained
positive for β-Gal expression) in arbitrary light units (ALU)
with standard error (SE) from a minimum of triplicate
experiments. Statistical analysis was performed using Student's
t test, P<0.05.
Western immunoblot assay
Transiently transfected cells were lysed in RIPA buffer
containing PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate,
and 0.1% sodium dodecyl sulfate (SDS). Cell lysates were
prepared by centrifugation at 14,000 rpm (Beckman, Fullerton,
CA) for 20 min at 4 °C. Equal amounts of proteins were mixed
with Laemmli buffer (62.5 mM Tris; pH 6.8), 2% SDS, 10%
glycerol, 0.2% bromophenol blue, and 100 mM dithiothreitol
(DTT). After boiling for 5 min, samples were electrophoresed
through 6 or 10% polyacrylamide gels. The fractionated
proteins were transferred to nitrocellulose membranes (Amer-
sham Pharmacia Biotechnology, Piscataway, NJ) at 100 V for
1 h at 4 °C. Membranes were then blocked in Tris-buffered
saline containing 5% nonfat milk and 0.1% Tween 20. Proteins
were detected with primary monoclonal anti-hemagglutinin
(HA) antibody (Covance) followed by an anti-mouse (Cell
Signaling Technology, Beverly, MA) immunoglobulin G (IgG)-
horseradish peroxidase-conjugated goat antibody. Blots were
developed using an enhanced chemiluminescence detection
system (Cell Signaling Technology).
Coimmunoprecipitation of p30II with p300
Sixty percent confluent 293T cells was cotransfected by
pME-p30IIHA, pME-p30IIHA serial deletion, or argininesubstitution mutants and pCMV-p300 using Superfect (Gibco
BRL, Gaithersburg MD). After 48 h, the transfected cells were
washed with PBS and resuspended in 400 μl of lysis buffer
containing 50 mM Tris–HCl (pH 8.0), 100 mM NaCl, 1 mM
phenylmethylsulfonyl fluoride (PMSF), 0.5 μg of leupeptin per
ml, and 1 μg of aprotinin per ml. Cell suspensions were
incubated on ice for 20 min and then lysed by homogenization.
The lysates were centrifuged at 14,000 rpm for 20 min at 4 °C
and incubated overnight at 4 °C with 100 ng of a polyclonal HA
antibody (Covance). After adding 40 μl of 100% of protein A-
agarose slurry, the mixture was incubated at 4 °C for 1 h. The
immunoprecipitated complexes were washed twice with 10
volumes of lysis buffer and three times with PBS buffer. The
components of the complexes were resolved on 6% SDS-
polyacrylamide gels and detected byWestern immunoblot assay
using anti-p300 antibody (Santa Cruz biotechnology, Santa
Cruz, CA). The density of each band was measured and
compared to wild type p30II using a commercial software
package (Gel-pro Analyzer software; Media Cybernatic Inc.,
San Diego, CA). Normal rabbit IgG was used as a negative
control in immunoprecipitation assays and equal amounts of
input cell extracts were processed to determine the expression of
p30II by Western immunoblot assay.
Localization of p30II and colocalization with CBP/p300 by
confocal microscopy
To detect cellular colocalization of p30II and p300 by
immunofluorescence, HeLa-Tat cells were seeded in two
chamber slides (Fisher Scientific) at approximately 50%
confluence 18 h prior to transfection. Transfection with 4 μg
of pME-p30II-HA wild-type or pME-p30IIHA serial deletion
mutants alone or with 2 μg of pCMV-p300 was performed using
Superfect (Gibco BRL). At 48 h post-transfection, media were
removed and cells were fixed for 15 min using 4%
paraformaldehyde. Cells were then incubated with FITC
(Fluorescin isothyocyanate) conjugated anti-HA antibody
alone (diluted 1:1000; Santa Cruz) or with TRITC (Texas red
isothyocyanate) conjugated anti-p300 antibody (diluted 1:1000;
Molecular probes) in antibody dilution buffer containing
0.01 M sodium phosphate, 0.5 M NaCl, 0.5% Triton-X 100,
and 2% bovine serum albumin overnight at 4 °C. Actin
filaments were stained with Alexa Fluor 633 phalloidin and
nuclei were visualized using Hoechst 33342, trihydrochloride,
and trihydrate-FluoroPure grade (Invitrogen/Molecular Probes,
Carlsbad, CA). The expression of p30II-HA and p300 was
evaluated using Zeiss LSM 510 confocal microscope.
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